Our GMP-compliant biopharma plant planning services deliver systematic, risk-based facility planning solutions tailored for modern biomanufacturing sites, covering biologic drugs, vaccines, cell and gene therapies, and sterile pharmaceutical production facilities. All planning frameworks strictly align with FDA cGMP, EMA Annex 1, PIC/S and ISPE international standards, ensuring every layout, process flow and utility configuration is audit-ready and regulation-compliant from the initial design stage.
We provide full-lifecycle planning consultancy ranging from project feasibility study, site selection and master facility layout planning, to user requirement specification (URS) formulation, cleanroom zoning optimization, contamination control strategy planning, and process flow rationalization. Our team eliminates common planning defects including unreasonable personnel and material circulation, cross-contamination risks, functional zone mismatch, and redundant utility configuration, building scientific, efficient and compliant plant operational logic.
Adopting quality-by-design and lean engineering principles, we customize scalable planning schemes for diversified project scenarios, including greenfield new plant construction, modular pilot facility layout, and GMP upgrading and reconstruction of existing production workshops. We optimize production efficiency, space utilization and long-term expandability while controlling overall project investment, avoiding costly late-stage design adjustments and construction rework.
Supported by complete planning documents, risk assessment reports and validation-oriented design guidelines, our professional plant planning lays a solid foundation for subsequent engineering construction, CQV implementation and regulatory inspection, helping biopharma enterprises achieve fast, stable and compliant production launch.
